0.75%
-17.74%
-5.61%
-54.02%
-59.40%
-66.69%
-48.22%
AI Spotlight on HYL
Company Description
Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health, oncology, women's health, and other major therapeutic areas.The company offers cardiovascular products for atrial fibrillation, acute coronary syndrome, advanced heart failure, congestive heart failure, acute coronary syndrome, and coronary heart disease.It also provides other products, such as post operation pain, dental indications, severe and recurring vulvovaginal candidiasis, acute myeloid leukemia and small cell lung cancer, IC/PBS, attention deficit hyperactivity disorder, and viral infection.
Hyloris Pharmaceuticals SA was incorporated in 2012 and is headquartered in Liège, Belgium.
Market Data
| Last Price | 5.38 |
| Change Percentage | 0.75% |
| Open | 5.36 |
| Previous Close | 5.34 |
| Market Cap ( Millions) | 151 |
| Volume | 3786 |
| Year High | 13.3 |
| Year Low | 2.89 |
| M A 50 | 5.72 |
| M A 200 | 7.85 |
Financial Ratios
| FCF Yield | -5.96% |
| Dividend Yield | 0.00% |
| ROE | -22.39% |
| Debt / Equity | 4.48% |
| Net Debt / EBIDTA | 327.15% |
| Price To Book | 3.85 |
| Price Earnings Ratio | -17.18 |
| Price To FCF | -16.78 |
| Price To sales | 49.33 |
| EV / EBITDA | -13.93 |
News
- Mar -14 - Hyloris Reports Full Year Results for 2023 & Provides Business Outlook
- Mar -14 - Communication at the request of the FSMA on the transactions with Qliniq
- Mar -08 - Hyloris to Report 2023 Full-Year Results on 14 March 2024
- Feb -27 - Hyloris Announces Launch of Maxigesic® IV in the U.S. and approval In Canada
- Feb -14 - Hyloris Enrolls First Patient in Phase 3 Clinical Trial for its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures
- Jan -30 - Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC)
- Jan -18 - Hyloris Broadens Pipeline with new Product Candidate for Vulvar Lichen Sclerosus (VLS)
- Jan -16 - Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML)
- Jan -16 - Pleco Therapeutics receives FDA Orphan Drug Designation
- Dec -26 - Hyloris Announces Positive Clinical Study Results for Valacyclovir Oral Suspension (HY-029)
- Dec -21 - Hyloris Broadens Pipeline with new Product Candidate in Burning Mouth Syndrome
- Dec -04 - Hyloris announces US FDA approval for Podofilox Gel
- Oct -24 - Hyloris Announces Out-Licensing of Atomoxetine Oral Liquid in Canada
- Oct -18 - Hyloris Pharma wins US FDA approval for pain treatment
- Oct -18 - Hyloris announces U.S. FDA Approval of Maxigesic® IV
- Sep -06 - Hyloris Pharmaceuticals Reports 2023 Half-Year Results and provides Business Outlook
- Jun -22 - Hyloris announces enrolment of first patient in a 4-arm clinical trial of Alenura(TM)
- Jun -13 - Hyloris shareholders approve all resolutions at the Annual General Meeting
- Jun -08 - Hyloris has been granted EUR 1 million in non-dilutive funding from the Walloon Region
- May -02 - Hyloris announces potential registration date for Maxigesic® IV in the US
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Pharmaceuticals
Expected Growth : 9.27 %
What the company do ?
Hyloris Pharmaceuticals SA is a Belgian pharmaceutical company focused on developing and commercializing innovative therapeutic solutions.
Why we expect these perspectives ?
Hyloris Pharmaceuticals SA's 9.27% growth is driven by increasing demand for specialty medicines, strategic partnerships, and expansion into emerging markets. Additionally, the company's focus on rare disease treatments and innovative pipeline products contribute to its growth momentum.
Hyloris Pharmaceuticals Sa Products
| Product Range | What is it ? |
|---|---|
| Rybelsus | Rybelsus is an oral glucagon-like peptide-1 (GLP-1) receptor agonist, used to treat type 2 diabetes. |
| Xerava | Xerava is a tetracycline-class antibacterial, used to treat community-acquired bacterial pneumonia (CABP). |
| Suliqua | Suliqua is a fixed-dose combination of insulin glargine and lixisenatide, used to treat type 2 diabetes. |
| Adlyxin | Adlyxin is a glucagon-like peptide-1 (GLP-1) receptor agonist, used to treat type 2 diabetes. |
Hyloris Pharmaceuticals SA's Porter Forces
Threat Of Substitutes
The threat of substitutes for Hyloris Pharmaceuticals SA is moderate due to the presence of alternative pharmaceutical companies offering similar products.
Bargaining Power Of Customers
The bargaining power of customers for Hyloris Pharmaceuticals SA is low due to the company's strong brand reputation and limited availability of alternative products.
Bargaining Power Of Suppliers
The bargaining power of suppliers for Hyloris Pharmaceuticals SA is moderate due to the presence of multiple suppliers and the company's moderate dependence on them.
Threat Of New Entrants
The threat of new entrants for Hyloris Pharmaceuticals SA is high due to the attractiveness of the pharmaceutical industry and the ease of entry for new companies.
Intensity Of Rivalry
The intensity of rivalry for Hyloris Pharmaceuticals SA is high due to the presence of multiple competitors and the high stakes in the pharmaceutical industry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 12.00% |
| Debt Cost | 6.77% |
| Equity Weight | 88.00% |
| Equity Cost | 6.77% |
| WACC | 6.77% |
| Leverage | 13.64% |
Hyloris Pharmaceuticals SA : Quality Control
Hyloris Pharmaceuticals SA passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CGEN | Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of … |
| GUBRA.CO | Gubra A/S operates as a biotech company with two primary areas of business: pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs. The CRO segment offers … |
| MDWD | MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a … |
| BIOA-B.ST | BioArctic AB (publ), a research-intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops BAN2401, an immunotherapy, which is in Phase III clinical trials … |
| BSLN.SW | Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Gubra
A-Score
1-Year Total Return ->
🥈
MediWound
A-Score
1-Year Total Return ->
🥉
Basilea Pharmaceutica
A-Score
1-Year Total Return ->
4
BioArctic
A-Score
1-Year Total Return ->
5
Compugen
A-Score
1-Year Total Return ->
6
